PR Newswire - Brii Bio Delivers First Head-to-Head Comparison of...
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-...
Read More

ภาษาไทย
English